Informational Only · Not Legal Advice · No Attorney-Client Relationship · Editorial Policy

A Bone-Growth Device Used Without Adequate Warnings: What Could Make a Settlement Offer Fair—or Dangerously Low?

A settlement offer for a bone-growth device injury is fair when it reflects your own medical course — the revision surgeries, the swallowing or breathing complications, the lost income — rather than an average struck across thousands of claimants. It is dangerously low when it is a per-head division of a lump sum, quoted to you before anyone has priced your liens, your attorney's fee, and the specific legal defenses that apply to your device.

Two numbers frame the problem. Medtronic's earlier INFUSE deal paid $22 million to resolve 950 claims, which works out to roughly $23,000 per person before fees and medical liens are taken out. Whether that figure is a floor or a ceiling for your case depends almost entirely on how your device reached the market — and that is a question of regulatory paperwork, not of how badly you were hurt.

Table of Contents

What "inadequate warnings" means in a bone-growth case

A failure-to-warn claim says the manufacturer knew about a risk, had a duty to tell surgeons and patients, and did not do it clearly enough. For rhBMP-2 — recombinant human bone morphogenetic protein-2, the biologic in Medtronic's INFUSE bone graft that stimulates the body to grow new bone — the warning gap is documented in a federal investigation. The U.S. Senate Finance Committee's October 2012 staff report found that Medtronic employees collaborated with physician authors to edit and in some cases write segments of published rhBMP-2 studies without disclosing their roles, and that the published papers did not adequately present serious side-effect risks. The scale of that influence matters to a jury.

The Regulatory Affairs Professionals Society reported in October 2012 that the investigation reviewed more than 5,000 Medtronic documents covering 13 INFUSE studies and found roughly $210 million in payments to physician authors over about 15 years. Medtronic said it disagreed that it had improperly influenced or authored any peer-reviewed manuscript. The harm pattern is separately documented. A systematic review and meta-analysis published in Annals of Internal Medicine in June 2013 found that rhBMP-2 used in anterior cervical spine fusion was associated with statistically significant increases in overall adverse events, wound complications, and dysphagia or dysphonia — difficulty swallowing or hoarseness from airway and soft-tissue swelling in the neck. Those are the injuries that inadequate-warning claims are built on.

The one question that decides your case's value

Before you weigh any dollar figure, find out which FDA pathway your device went through. In *Riegel v. Medtronic*, decided 8–1 on February 20, 2008, the Supreme Court held that the Medical Device Amendments preempt state-law safety and effectiveness claims against devices approved through FDA premarket approval. A Congressional Research Service report on the decision explains what survives: only "parallel" claims, meaning claims premised on a violation of an FDA requirement the manufacturer actually broke. That is why two patients with identical neck injuries can be offered wildly different sums.

A premarket-approval (PMA) device carries a preemption shield that can wipe out a standard failure-to-warn count, so offers on those claims are discounted hard. A device cleared through 510(k) — the faster route for products shown to be substantially equivalent to something already on the market — gets no such shield. Device class is not frozen, either. FDA's final order published in the Federal Register on April 16, 2026 reclassified non-invasive bone growth stimulators, product codes LOF and LPQ, from class III to class II with special controls at 21 CFR 890.5870. Ask your lawyer, in writing, which pathway and class applied to your specific device on the date it was implanted or prescribed.

Benchmarks an offer should be measured against

A single number in isolation tells you nothing. Compare it to the known per-claimant history and to your own documented losses.

  • **The 2014 benchmark.** The Star Tribune reported that Medtronic settled 950 INFUSE claims for $22 million — about $23,000 each gross. If your injuries are far more severe than the median in that group and your offer sits near that figure, ask why.
  • **The later resolution.** Medtronic's FY2018 Form 10-K disclosed that law firms representing approximately 6,000 claimants had asserted or intended to assert INFUSE personal-injury claims, and that as of June 1, 2017 the company had reached agreements to settle substantially all of them without admitting wrongdoing. Volume settlements of that size are typically graded by injury tier, not paid flat.
  • **Your net, not your gross.** Subtract the contingency fee, case costs, and every medical lien — private insurer, Medicare, Medicaid, workers' compensation. A $75,000 gross offer with a $30,000 unresolved Medicare claim is not a $75,000 offer.
  • **Your future.** Price the revision surgery already recommended, the swallowing therapy, and the earnings you will not recover. An offer that covers only past bills is a partial offer.

How a court tests fairness — and when nobody tests yours

If your claim is resolved as a certified class action, a judge must approve it. Under Federal Rule of Civil Procedure 23(e)(2), a court may approve a binding class settlement only after a hearing and only on finding it fair, reasonable, and adequate. The rule directs the judge to weigh adequacy of representation, whether the deal was negotiated at arm's length, the adequacy of relief in light of the costs, risks, and delay of trial, the proposed method of distributing payments, and the terms of the attorney's fee award — plus whether class members are treated equitably relative to each other. Most device personal-injury claims are not resolved that way. They settle individually or through an aggregate inventory deal, where no judge applies the Rule 23(e)(2) factors to your number.

You are the only reviewer. Borrowing the rule's checklist is still useful: ask what the distribution grid is, which tier you were placed in, what the fee and cost deductions are, and why a claimant with your injury profile was slotted where they were. Watch for the pressure tactics that accompany a low aggregate offer: a participation threshold requiring most claimants to accept before the deal funds, a short acceptance window, and a refusal to break the gross figure into components. None of those is illegal. All of them are reasons to get the grid in writing before you sign a release.

Why the warning gap is provable, and what to gather now

The clinical response to these risks is itself evidence. A study of U.S. bone morphogenetic protein use in spinal fusion from 2002 to 2012, indexed in PubMed, documented that use fell significantly after FDA's 2008 Public Health Notification about life-threatening complications in cervical-spine procedures and after disclosures of payments to pivotal-trial surgeons. Surgeons changed their practice once they had the information — which supports the argument that the earlier warnings were inadequate and that the gap was later corrected.

Build your file around dates. Pull the operative report and the implant sticker or device identifier from the hospital record, the manufacturer and model, the consent form you signed, and every note describing swallowing trouble, hoarseness, airway swelling, bone growing where it should not, or a failed fusion requiring revision. The implantation date, set against the 2008 notification and the 2012 Senate findings, is what determines whether the manufacturer already knew what it did not tell your surgeon. Also check your statute of limitations immediately, since it runs from a date your state defines — often when you discovered or reasonably should have discovered the injury and its cause, not the surgery date. A claim that has expired has a settlement value of zero regardless of how strong the warning evidence looks.

Frequently Asked Questions

Does it matter that the manufacturer settled without admitting wrongdoing?

No. Medtronic's FY2018 Form 10-K recorded agreements to settle substantially all of roughly 6,000 claimants' INFUSE claims without any admission. A no-admission clause is standard and does not reduce what you are paid.

Can I reject an aggregate settlement and keep litigating?

In an individual or inventory settlement, yes — you are not bound unless you sign a release. In a certified class action, you are bound once the court approves under Rule 23(e)(2) unless you opt out during the window the notice specifies.

My device was a non-invasive bone growth stimulator, not an implanted graft. Does any of this apply?

The preemption analysis does, and in your favor. FDA's April 16, 2026 final order placed non-invasive bone growth stimulators (codes LOF and LPQ) in class II with special controls, and 510(k)-cleared devices do not receive the premarket-approval shield that *Riegel* created.


You Might Also Like

We use essential cookies to make this site work and remember your preferences. We do not use advertising or analytics cookies. Privacy Policy.